« Return to News | Clinical Intelligence

Complete Genomics introduces new grant program

Tuesday, July 5, 2011 12:13 PM

Complete Genomics, a human genome sequencing company, has announced a new cancer grant program. Winning research applications will receive complete human genome sequencing of eight genomes—four tumor/normal pairs. Four winning entries will be chosen: two each from the United States and Europe.

Complete Genomics is accepting grant applications for cancer-specific research projects using its complete human genome sequencing service until July 29, 2011.

Applications will be evaluated by an internal panel of scientific experts at Complete Genomics. Winners will be notified by Aug. 12 and will be required to submit their samples by Sept. 16. All applicants will be eligible for a discount on their next complete human genome sequencing project.

"We are delighted to have the opportunity to provide pioneering scientists with complete human genome sequencing and research-ready data that they can immediately use to gain insights into the characterization and possible treatment of various cancers, " said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.